Annukka M Lahtinen1, Aki S Havulinna2, Antti Jula2, Veikko Salomaa2, Kimmo Kontula3. 1. Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. 2. National Institute for Health and Welfare, Helsinki and Turku, Finland. 3. Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. Electronic address: kimmo.kontula@hus.fi.
Abstract
OBJECTIVE: This study aimed to investigate the exact prevalence of familial hypercholesterolemia (FH) in the general population, taking advantage of the fact that five low-density lipoprotein receptor (LDLR) founder mutations account for 78% of FH cases in Finland. METHODS: Five LDLR founder mutations, FH-North Karelia, FH-Helsinki, FH-Pogosta, FH-Turku, and FH-Pori, were genotyped and serum lipid levels were measured in a large collection of Finnish population cohorts (n = 28,465), including the National FINRISK Study and the Health 2000 Study. Follow-up data were obtained from national healthcare registries. RESULTS: The combined prevalence of three of the five FH founder mutations (FH-North Karelia, FH-Helsinki, and FH-Pogosta) was 0.12% (95% CI 0.07-0.16%), while FH-Turku and FH-Pori were not identified in the present sample cohort. Our data suggest that the estimated total prevalence of FH in Finland is at least 0.17%. Approximately half of the 35 FH mutation carriers used lipid-lowering medication at the time of the baseline investigation. LDL cholesterol levels were on average 2 mmol/L higher in mutation carriers than in non-carriers (p < 0.001) but did not differ between FH mutation carriers with and without lipid-lowering medication. During the follow-up for 13 years, one mutation carrier encountered a probable sudden cardiac death, two mutation carriers suffered from a stroke, and one from a myocardial infarction. CONCLUSIONS: In Finland, at least 1 in 600 individuals is estimated to have FH. A marked undertreatment of FH was observed in LDLR mutation carriers.
OBJECTIVE: This study aimed to investigate the exact prevalence of familial hypercholesterolemia (FH) in the general population, taking advantage of the fact that five low-density lipoprotein receptor (LDLR) founder mutations account for 78% of FH cases in Finland. METHODS: Five LDLR founder mutations, FH-North Karelia, FH-Helsinki, FH-Pogosta, FH-Turku, and FH-Pori, were genotyped and serum lipid levels were measured in a large collection of Finnish population cohorts (n = 28,465), including the National FINRISK Study and the Health 2000 Study. Follow-up data were obtained from national healthcare registries. RESULTS: The combined prevalence of three of the five FH founder mutations (FH-North Karelia, FH-Helsinki, and FH-Pogosta) was 0.12% (95% CI 0.07-0.16%), while FH-Turku and FH-Pori were not identified in the present sample cohort. Our data suggest that the estimated total prevalence of FH in Finland is at least 0.17%. Approximately half of the 35 FH mutation carriers used lipid-lowering medication at the time of the baseline investigation. LDL cholesterol levels were on average 2 mmol/L higher in mutation carriers than in non-carriers (p < 0.001) but did not differ between FH mutation carriers with and without lipid-lowering medication. During the follow-up for 13 years, one mutation carrier encountered a probable sudden cardiac death, two mutation carriers suffered from a stroke, and one from a myocardial infarction. CONCLUSIONS: In Finland, at least 1 in 600 individuals is estimated to have FH. A marked undertreatment of FH was observed in LDLR mutation carriers.
Authors: Alicia R Martin; Konrad J Karczewski; Sini Kerminen; Mitja I Kurki; Antti-Pekka Sarin; Mykyta Artomov; Johan G Eriksson; Tõnu Esko; Giulio Genovese; Aki S Havulinna; Jaakko Kaprio; Alexandra Konradi; László Korányi; Anna Kostareva; Minna Männikkö; Andres Metspalu; Markus Perola; Rashmi B Prasad; Olli Raitakari; Oxana Rotar; Veikko Salomaa; Leif Groop; Aarno Palotie; Benjamin M Neale; Samuli Ripatti; Matti Pirinen; Mark J Daly Journal: Am J Hum Genet Date: 2018-04-26 Impact factor: 11.025
Authors: Akl C Fahed; Ruby Khalaf; Rony Salloum; Rabih R Andary; Raya Safa; Inaam El-Rassy; Elie Moubarak; Sami T Azar; Fadi F Bitar; Georges Nemer Journal: Mol Genet Genomic Med Date: 2016-02-24 Impact factor: 2.183
Authors: Andrzej Pajak; Krystyna Szafraniec; Maciej Polak; Wojciech Drygas; Walerian Piotrowski; Tomasz Zdrojewski; Piotr Jankowski Journal: Arch Med Sci Date: 2016-05-05 Impact factor: 3.318
Authors: Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries Journal: J Med Genet Date: 2016-11-07 Impact factor: 6.318
Authors: Zuhier Ahmed Awan; Omran M Rashidi; Bandar Ali Al-Shehri; Kaiser Jamil; Ramu Elango; Jumana Y Al-Aama; Robert A Hegele; Babajan Banaganapalli; Noor A Shaik Journal: Front Med (Lausanne) Date: 2021-06-25
Authors: Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu Journal: BMJ Open Date: 2017-09-01 Impact factor: 2.692